地拉罗司(恩瑞格)哪里有售？

In 2005, Enrig was the first oral iron chelator approved by the FDA for routine use, and deferasirox is now commercially available in more than 80 countries. Deferasirox (Enrige) was finally approved for marketing in China in 2010, and is used to treat chronic iron overload caused by frequent blood transfusions (monthly dosage of concentrated red blood cells ≥7 mL/kg) in patients with β-thalassemia over 6 years old. For children under 6 years old and iron overload caused by other transfusion-dependent diseases, the safety and effectiveness data of deferasirox (Enrige) in Chinese patients are limited, and it is recommended to use it with caution based on the specific conditions of the patients.

Deferasirox (Enrego), which is available in China, is an imported version originally developed by Novartis. Patients can go to major domestic hospitals to buy it through pharmacies, but the price is staggering. It costs about $24,000 a month, which is beyond the reach of many working-class families, not to mention some patients whose family background is not very good. Such astronomical treatment costs make them frustrated. However, the rise of generic drugs has given these families renewed hope. Currently, there are generic and original versions of Deferasirox (Enrego) available in India, but the price is very satisfactory.

Swiss Novartis imported it to India (Enrig), the specification is 400mg*30 tablets/box, and the price is about 700$. The specifications of Deferasirox (Enrego) produced by Indian pharmaceutical companies are 500*30 tablets/box, and the price is about $500. If you want to buy the Indian version of Deferasirox, you can contact domestic and overseas medical institutions (such as Medical Companion Travel) to purchase.